APM Human Services (ASX:APM) confirms takeover bid from major shareholder
APM Human Services's major shareholder, Madison Dearborn Capital Partners, which holds over 30% of the company's stock, has emerged as the frontrunner for a takeover. A letter of intention has been received from Madison Dearborn to acquire 100% of APM's shares. APM seeks an extension for considering the offer, aiming to resume trading on April 8. The company suspended trading to address interest from potential buyers after a failed $1.8 billion bid by CVC. Read More #News #ASX #Capital
⬆ $Samsonite(01910)$ - This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and how those spreads have changed over the last week. Continue reading on Smartkarma:- https://www.smartkarma.com/insights/mostly-assia-pac-m-a-alumina-superloop-qantm-samsonite-esr-apm-adbri-csr-outsourcing?utm_source=tiger_community By David Blennerhassett, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/david-blennerhassett?utm_source=tiger_community On Samsonite (01910):- https://www.smartkarma.com/entities/samsonite-international-sa?utm_source=tiger_community
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.
04-30
Annual Report
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]